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ABSTRACT 
Clinical, pathological and genetic overlap between sporadic frontotemporal dementia (FTD), Alzheimer’s 
disease (AD) and Parkinson’s disease (PD) has been suggested; however the relationship between these 
disorders is still not well understood. Here we evaluated genetic overlap between FTD, AD and PD to 
assess shared pathobiology and identify novel genetic variants associated with increased risk for FTD. 
Summary statistics were obtained from the International FTD Genomics Consortium, International PD 
Genetics Consortium, International Genomics of AD Project (n>75,000 cases and controls). We used 
conjunction false discovery rate (FDR) to evaluate genetic pleiotropy and conditional FDR to identify 
novel FTD associated SNPs. Relevant variants were further evaluated for expression quantitative loci. 
We observed SNPs within the HLA, MAPT and APOE regions jointly contributing to increased risk for 
FTD and AD or PD. By conditioning on polymorphisms associated with PD and AD, we found 11 loci 
associated with increased risk for FTD. Meta-analysis across two independent FTD cohorts revealed a 
genome-wide signal within the APOE region (rs6857, 3’-UTR=PVRL2, p=2.21 x 10
-12
), and a suggestive 
signal for rs1358071 within the MAPT region (intronic=CRHR1, p=4.91 x 10
-7
) with the effect allele 
tagging the H1 haplotype. Pleiotropic SNPs at the HLA and MAPT loci associated with expression 
changes in cis genes supporting involvement of intracellular vesicular trafficking, immune response and 
endo/lysosomal processes.  
Our findings demonstrate genetic pleiotropy in these neurodegenerative diseases and indicate that 
sporadic FTD is a polygenic disorder where multiple pleiotropic loci with small effects contribute to 
increased disease risk. 
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INTRODUCTION 
Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by progressive impairment 
of behaviour, cognition and executive function or language.[1] Recent converging evidence suggests 
clinical, pathological and genetic overlap between FTD and other common neurodegenerative diseases 
including Alzheimer’s disease (AD) and Parkinson’s disease (PD). 
From a clinical perspective, FTD and AD can sometimes be difficult to distinguish at onset or during 
disease progression:[2] non-cognitive manifestations such as mood changes, psychosis or variable social 
conduct can characterize the initial phases of AD patients.[3] Similarly, cognitive dysfunctions such as 
changes in abstract thinking or poor judgment, planning and difficulty in completing tasks become evident 
in either condition as the disease progresses.[4] This might partially reflect the fact that FTD and AD are 
associated with progressive impairment of similar brain circuits (frontal, pre-frontal or temporal lobes 
and/or subcortical regions).[5] Of note, among the primary progressive aphasia (PPA) cases in FTD, 
logopenic progressive aphasia (LPA) has been suggested as an atypical early presentation of AD.[6] In 
addition, the subtype called frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-
17) – linked to mutations in the microtubule-associated protein tau (MAPT)[7] and progranulin (GRN) 
genes[8] – shows parkinsonian-like syndrome,[9] whilst dementia features can be found in up to 30-80% 
of PD cases (PDD) in later stages of the disease.[10] 
From a pathological perspective, abnormal intracellular accumulation of the tau protein is seen in both 
FTD and AD.[11] Additionally, TDP-43 pathology has been reported in both AD and FTD at different 
disease stages,[12] and in some rare PD cases associated with variability in LRRK2 (leucine-rich repeat 
kinase 2).[13] 
From a genetic perspective, distinct genetic and genome-wide scale studies have suggested potential 
genetic overlap between FTD, AD and PD at specific loci. The MAPT gene on chromosome 17 has been 
extensively investigated in FTD[11] and has been recently implicated in AD[14] and PD[15] suggesting 
that tau pathology might jointly contribute to FTD, AD and PD. In addition, genome-wide association 
studies (GWAS) have revealed that common genetic variants within the HLA region on chromosome 6 
increase risk for FTD,[16] AD[17] and PD.[18] 
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Evaluating genetic overlap between complex traits is based on the concept that gene(s) or genetic 
variant(s) can influence more than one distinct phenotype (= genetic pleiotropy).[19] Availability of large-
scale genetic datasets (e.g. genome-wide summary statistics) is a key to estimate the level of genetic 
overlap, or genetic pleiotropy, across diverse traits including groups of related disorders.[20]  
We have recently developed methods to evaluate genetic pleiotropy across different disorders (identifying 
novel genetic variants associated with various conditions including multiple sclerosis and AD).[14, 21, 22] 
In the current work we sought to apply these methods taking advantage of existing large-scale genetic 
data (i.e. summary statistics) for FTD,[16] AD[23] and PD[24] to identify genetic overlap, i.e. pleiotropic 
effects, across these neurodegenerative disorders. 
 
MATERIALS AND METHODS 
Participant Samples 
We evaluated complete summary statistics (p-values and odds ratios) from GWAS data of clinically 
diagnosed FTD,[16] AD[23] and PD.[24] We used AD-GWAS summary statistic data from the 
International Genomics of AD Project (IGAP Stage 1), which consisted of 17,008 AD and 37,154 controls 
with genotyped or imputed data at 7,055,881 SNPs (Table 1, for additional details see).[23] We obtained 
PD-GWAS summary statistic data from the International Parkinson’s Disease Genetics Consortium 
consisting of 5,333 cases and 12,019 controls with genotyped and imputed data at 7,689,524 SNPs 
(Table 1, for additional details see).[24] 
We examined FTD summary statistic GWAS data (discovery + replication phase) from the International 
FTD Genomics Consortium (IFGC).[16] As our discovery cohort, we used the IFGC Phase 1 cohort 
(Table 1), consisting of 2,154 FTD cases and 4,308 controls with genotyped and imputed data at 
6,026,384 SNPs.[16] To replicate our findings from the discovery analyses using IFGC Phase 1, we 
assessed the p-values of pleiotropic SNPs (conditional FDR < 0.05; see Statistical analysis below) within 
the IFGC Phase 2 sample. The IFGC Phase 2 sample consisted of 1,372 FTD cases and 5,094 controls 
genotyped using a partially custom-designed Illumina NeuroX chip (Table 1, for details see).[16] The 
IFGC Phase 1+2 multicenter GWAS has been described in detail elsewhere.[16] Briefly, 44 international 
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research groups contributed samples to this two-stage clinical FTD-GWAS. We evaluated genetic data 
from patients clinically diagnosed with behavioral variant FTD (bvFTD), semantic dementia (SD), 
progressive nonfluent aphasia (PNFA) and FTD with motor neuron disease (FTD-MND). As described in 
the original study we excluded any cases with clinically diagnosed logopenic progressive aphasia (LPA), 
progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD). In this study, MAPT and GRN 
mutation carriers were excluded whereas individuals with C9orf72 expansions were not excluded 
because this locus was identified subsequent to original sample collection. The relevant institutional 
review boards or ethics committees approved the research protocol of the individual GWAS used in the 
current analysis, and all human participants gave written informed consent. 
Table 1. Summary data from all GWAS used in the current study. 
 
 
 
 
 
 
 
 
Statistical analysis  
Using recently developed statistical methods to evaluate pleiotropic effects, we evaluated SNPs 
associating with FTD, AD and PD. These methods have been described in extensive detail in a number of 
recent publications.[14, 17, 22] Briefly, for given associated phenotypes A and B, pleiotropic enrichment 
of phenotype A with phenotype B exists if the proportion of SNPs or genes associated with phenotype A 
increases as a function of increased association with phenotype B. To assess enrichment, we 
constructed fold-enrichment plots of nominal –log10(p) values for all FTD-SNPs and a subset of SNPs 
determined by the significance of their association with PD and AD. In fold-enrichment plots, the presence 
of enrichment is reflected by an upward deflection of the curve for phenotype A if the degree of deflection 
Disease/Trait Total N # SNPs Reference 
Frontotemporal 
Dementia (FTD) – 
IFGC phase 1 
 6,462 6,026,384 [16] 
Frontotemporal 
Dementia (FTD) – 
IFGC phase 2 
 6,466 
Illumina 
NeuroX Chip 
[16] 
Alzheimer’s disease 
(AD) – Phase 1 
 
54,162 
 
 
7,055,881 
 
 
[23] 
Parkinson’s disease 
(PD) 
 17,352 7,689,524 [24] 
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from the expected null line is dependent on the degree of association with phenotype B. To assess for 
polygenic effects below the standard GWAS significance threshold, we focused the fold-enrichment plots 
on SNPs with nominal –log10(p) < 7.3 (corresponding to p-value > 5x10
-8
). The enrichment can be directly 
interpreted in terms of true discovery rate (TDR = 1 – False Discovery Rate [FDR]).[22]  
To identify specific loci involved in both FTD and AD or FTD and PD, we computed conjunction FDR.[17] 
Conjunction FDR, denoted by FDRtrait1& trait2 is defined as the posterior probability that a SNP is null for 
either phenotype or both simultaneously, given the p-values for both traits are as small, or smaller, than 
the observed p-values. A conservative estimate of the conjunction FDR is given by the maximum statistic 
in taking the maximum of FDRtrait1|trait2 and FDR trait2|trait1.[17] We used an overall FDR threshold of < 0.05, 
which means 5 expected false discovery per hundred reported. Additionally, we constructed Manhattan 
plots based on the ranking of conjunction FDR to illustrate the genomic location of the pleiotropic loci.[17] 
To identify specific FTD loci we computed conditional FDR.[14, 22] The standard FDR framework derives 
from a model that assumes the distribution of test statistics in a GWAS can be formulated as a mixture of 
null and non-null effects, with true associations (non-null effects) having more extreme test statistics, on 
average, than false associations (null effects). The conditional FDR is an extension of the standard FDR, 
which incorporates information from GWAS summary statistics of a second phenotype to adjust its 
significance level. The conditional FDR is defined as the probability that a SNP is null in the first 
phenotype given that the p-values in the first and second phenotypes are as small as, or smaller, than the 
observed ones. It is important to note that ranking SNPs by standard FDR or by p-values both give the 
same ordering of SNPs. In contrast, if the primary and secondary phenotypes are related genetically, 
conditional FDR re-orders SNPs, and results in a different ranking than that based on p-values alone. We 
used an overall FDR threshold of < 0.05, which means 5 expected false discovery per hundred reported. 
Additionally, we constructed Manhattan plots based on the ranking of conditional FDR to illustrate the 
genomic location of the pleiotropic loci. In all analyses, we controlled for the effects of genomic inflation 
by using intergenic SNPs.[14, 22] Detailed information on fold enrichment and conditional Q-Q plots, 
Manhattan plots, and conditional FDR can be found in prior reports.[14, 22]  
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For loci with conditional FDR < 0.05, we performed a fixed effects, inverse variance weighted meta-
analysis across the discovery and replication FTD cohorts (IFGC Phases 1 and 2, total n = 3,526 FTD 
cases and 9,402 healthy controls) using the R package meta (http://CRAN.R-
project.org/package=meta).[25]  Briefly, the fixed effects, inverse variance weighted meta-analysis 
summarizes the combined statistical support across independent studies under the assumption of 
homogeneity of effects. Individual study β estimates (log odds ratios) are averaged, weighted by the 
estimated standard error. 
Expression quantitative trait loci (QTL)   
For the expression quantitative trait loci (eQTL) analyses, we used data generated within the Braineac 
(http://www.braineac.org) and GTEx (http://www.gtexportal.org/home/) projects. Briefly, in braineac, eQTL 
data was generated from 101 neuropathologically defined controls in the following 10 brain regions: 
cerebellar cortex, frontal cortex, hippocampus, medulla (specifically inferior olivary nucleus), occipital 
cortex (specifically primary visual cortex), putamen, substantia nigra, thalamus, temporal cortex, and 
intralobular white matter. In GTEx eQTL data was available for the following 10 brain regions: anterior 
cingulate cortex (BA24; n=72), caudate (basal ganglia; n=100), cerebellar hemisphere (n=89), cerebellum 
(n=103), cortex (n=96), frontal cortex (BA9; n=92), hippocampus (n=81), hypothalamus (n=81), nucleus 
accumbens (basal ganglia; n=93) and putamen (basal ganglia; n=82). 
Each eQTL was within +/- 1MB of each SNP and the significance threshold was p<1x10
-5 
as per website 
curators. 
 
RESULTS 
Polygenic enrichment in FTD as a function of AD and PD 
We observed enrichment for FTD SNPs (IFGC Phase 1) across different levels of significance of 
association with AD and PD (Figure 1). For progressively stringent p-value thresholds of FTD-SNPs (i.e. 
increasing values of nominal –log10PFTD ≥ 6), we found 140-fold and 120-fold pleiotropic enrichment as a 
function of AD (-log10PAD ≥ 3.0) and PD (-log10PPD ≥ 3.0) SNPs, respectively (Figure 1). Although 
decreased in magnitude, we observed a similar pattern of enrichment for AD- and PD-SNPs conditional 
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on FTD-SNPs suggesting symmetric genetic overlap between the three neurodegenerative diseases 
(Supplementary Figure 1). 
Conjunction FDR identifies shared FTD loci  
At a conjunction FDR < 0.05, we identified 11 SNPs that were associated with FTD and AD or PD (Figure 
2a, Table 2a). These included rs405509 (chromosome 19; intergenic; closest gene = APOE; conjunction 
trait = AD; min conjunction FDR = 0.0052) and rs9268877 (chromosome 6; intergenic; closest gene = 
HLA-DRA; conjunction trait = PD; min conjunction FDR = 0.048). We also found two pleiotropic loci in the 
MAPT haplotype-region, namely rs199528 (chromosome 17; intronic = WNT3; conjunction trait = PD; min 
conjunction FDR = 0.018) and rs1358071 (chromosome 17; intronic = CRHR1; conjunction trait = PD; min 
conjunction FDR = 0.02). We detected additional shared loci between FTD and PD on chromosomes 4 
(rs7664889, intronic = SCARB2), 10 (rs676768, intronic = VWA2), 12 (rs10784359, intronic = SLC2A13), 
13 (rs2893253; intergenic; closest gene = EFNB2) and 18 (rs12964543, intronic = ZNF532) (Table 2a). 
 
Table 2a. Overlapping loci between FTD, PD and AD at a conjunction FDR < 0.05 
 
SNP Position Chr Location; 
Nearest Gene 
Associated 
Phenotype 
Min 
Conj FDR 
FTD 
p-value 
Associated  
Phenotype  
p-value 
Direction 
of effect 
rs7664889 77087704 4 Intronic; 
SCARB2 
PD 4.84E-02 
 
1.75E-04 
 
 
8.88E-04 
 
++++ 
rs9268877 32431147 6 
 
Intergenic; 
HLA-DRA 
PD 4.84E-02 
 
 
1.04E-10 
 
 
7.41E-04 
 
++++ 
rs676768  116030773  10 
 
Intronic; 
VWA2 
PD 4.27E-02 
 
3.12E-04 
 
6.14E-04 
 
++++ 
rs10784359 
 
40445750  12 Intronic; 
SLC2A13  
PD 3.26E-02 
 
1.58E-04 
 
7.47E-05 
 
++++ 
rs2893253  107067203   13 Intergenic; 
EFNB2 
PD 3.55E-02 
 
2.02E-04 
 
 
1.11E-04 
 
++++ 
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rs199528  44843136  17 Intronic; 
WNT3 
PD 1.80E-02 
 
4.09E-05 
 
9.82E-16 
 
++++ 
rs1358071  43803189  17 Intronic; 
CRHR1  
PD 2.02E-02 
 
4.96E-05 
 
7.76E-15 
 
++++ 
rs12964543  56543095  18 Intronic; 
ZNF532 
PD 2.73E-02 
 
1.12E-04 
 
3.08E-04 
 
++++ 
rs405509 45408836 19 Intergenic; 
APOE 
AD 5.22E-03 
 
1.25E-05 
 
6.16E-70 
 
++++ 
  
 11 
Conditional FDR identifies novel FTD loci 
To identify novel SNPs associated with FTD we ranked IFGC Phase 1 FTD-SNPs conditional on their 
genetic association with AD and PD (conditional FDR), particularly focusing on those SNPs that did not 
reach genome-wide significant levels in the previous FTD-GWAS. At a conditional FDR < 0.05, we found 
13 novel FTD susceptibility loci: 11/13 polymorphisms were available for replication purposes within the 
IFGC2 cohort (7 actual SNPs and 4 proxies with linkage disequilibrium [LD] r
2 
≥ 0.7 and within 500KB 
distance from the reference SNP [based on HapMap 22/21]) (Figure 2b, Table 2b). Then, meta-analysis 
across IFGC Phase 1 and 2 cohorts revealed one genome-wide significant locus (p < 5 x 10
-8
): rs6857 on 
chromosome 19 (3’-UTR = PVRL2; conditioning trait = PD; reference allele = T; OR = 1.34; 95% CI = 
1.23-1.45; p = 2.21 x 10
-12
) (Table 2b, Figures 3a and 4a). We also found one suggestive locus (at p < 5 x 
10
-7
) on rs1358071 within the MAPT region on chromosome 17 (intronic = CRHR1; conditioning trait = 
PD; reference allele = A; OR = 1.19; 95% CI = 1.11-1.27; p = 4.91 x 10
-7
) (Table 2b, Figures 3b and 4b). 
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Table 2b. Novel SNPs showing association with FTD at conditional FDR < 0.05. Odds ratios provided for the reference allele  
 
SNP Position Chr Nearest 
Gene 
Reference 
Allele 
Associated 
phenotype 
Min Cond 
FDR 
IFGC 
Phase1 
p-value 
IFGC Phase1 
OR (95%CI) 
IFGC 
Phase 2 
p-value 
IFGC Phase 2 
OR (95% CI) 
Meta-analysis 
p-value 
Meta-
analysis OR 
(95% CI) 
rs4417745 241225364 2 
 
 
 
Intergenic; 
OTOS 
A 
 
 
PD 
 
2.73E-02 
 
2.52E-05 
 
 
1.36 
(1.18-1.57) 
 
0.47 1.06 
(0.90-1.25) 
3.20E-04 
 
1.22 
(1.09-1.36) 
rs7664889 77087704 4 
 
 
Intronic; 
SCARB2 
T 
 
PD 
 
3.23E-02 
 
1.75E-04 
 
0.73 
(0.62-0.86) 
 
0.82 0.98 
(0.81-1.18) 
3.18E-03 0.83 
(0.73-0.94) 
rs676768 116030773 10 
 
Intronic; 
VWA2
#
 
T 
 
PD 
 
4.25E-02 
 
3.12E-04 
 
0.78 
(0.68-0.90) 
 
0.55 0.96 
(0.82-1.11) 
2.40E-03 0.86 
(0.78-0.95) 
rs1328032 71420424 13 Intergenic; 
DACH1 
A AD 1.38E-02 
 
1.93E-07 
 
0.67 
(0.57-0.78) 
0.34 0.94 
(0.83-1.06) 
7.39E-05 0.80 
(0.72-0.88) 
rs2446406 51679783 15 Intronic; 
GLDN
#
 
A PD 2.59E-02 
 
7.18E-07 
 
0.81 
(0.74-0.88) 
0.40 0.96 
(0.87-1.06) 
2.24E-05 0.87 
(0.82-0.93) 
rs7184882 73737373 16 In orf; 
LOC10192
7998 
T AD 4.24E-02 
 
6.64E-07 
 
0.71 
(0.62-0.81) 
0.08 0.89 
(0.78-1.02) 
3.08E-06 0.78 
(0.71-0.86) 
rs199528 44843136 17 Intronic; 
WNT3 
T PD 1.79E-02 
 
4.09E-05 
 
0.82 
(0.74-0.90) 
0.03 0.89 
(0.80-0.99) 
9.59E-06 0.85 
(0.79-0.91) 
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Table 2b. Novel SNPs showing association with FTD at conditional FDR < 0.05. Odds ratios provided for the reference allele (continued) 
rs1358071 43803189 17 Intronic; 
CRHR1 
A PD 2.01E-02 
 
4.96E-05 
 
1.22 
(1.12-1.31) 
0.001 1.16 
(1.07-1.26) 
4.91E-07 1.19 
(1.11-1.27) 
 
rs12964543 56543095 18 Intronic; 
ZNF532
#
 
A PD 2.71E-02 
 
1.12E-04 
 
1.24 
(1.11-1.38) 
0.24 1.05 
(0.96-1.15) 
9.10E-04 1.12 
(1.05-1.2) 
rs6857 45392254 19 3’-UTR; 
PVRL2
#
 
T PD 4.69E-02 
 
7.03E-07 
 
1.31 
(1.18-1.46) 
4.46E-
07 
1.37 
(1.21-1.55) 
2.21E-12 1.34 
(1.23-1.45) 
rs405509 45408836 19 Intergenic; 
APOE 
T AD 5.26E-03 
 
1.25E-05 
 
1.18 
(1.09-1.27) 
0.93 1.0 
(0.92-1.09) 
5.98E-05 1.15 
(1.08-1.24) 
 
 
# rs676768 not available, proxy SNP rs12782946 from IFGC Phase 2 
# rs2446406 not available, proxy SNP rs2445742 from IFGC Phase 2 
# rs12964543 not available, proxy SNP exm2272683 from IFGC Phase 2 
# rs6857 not available, proxy SNP rs2075650 from IFGC Phase 2 
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Expression quantitative trait loci (eQTL) 
We evaluated potential biological relevance for each of the identified conjunction and conditional FDR 
SNPs (rs7664889, rs9268877, rs676768, rs10784359, rs2893253, rs199528, rs1358071, rs12964543, 
rs405509, rs4417745, rs1328032, rs2446406, rs7184882, rs6857, rs302665 and rs10507789) in human 
brain tissues assayed for genome-wide gene expression. There were 20 eQTLs in the Braineac dataset, 
whilst data extracted from GTEx indicated up to 144 significant eQTLs (Table 3). These were driven by 
rs199528 and rs1358071 (chr 17; MAPT-haplotype locus), and by rs9268877 (chr 6; HLA locus). No 
eQTLs were found for rs405509 and rs6857 (chr19; APOE locus). 
The eQTL data from Braineac and GTEx was cross-supportive in different brain regions, including frontal 
and temporal cortices, jointly indicating influence on expression levels of LRRC37A2, KANSL1, 
LRRC37A4 and CRHR1 for rs199528 and rs1358071; conversely, changes in expression of HLA-DPA1 
(from Braineac in frontal cortex), and HLA-DRB1 and HLA-DQA2 (from GTEx in subcortical regions and 
cerebellum) were evident for rs9268877 (Table 3). 
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Table 3. Summary of eQTL in brain from Braineac and GTEx 
 
SNP bp 
Risk 
allele 
Chr Location 
Nearest 
gene 
eQTL 
      
Braineac GTEx 
      
gene brain region p-value 
Effect of 
risk allele 
gene brain region p-value 
Effect of 
risk allele 
rs7664889 77087704 / 4 Intronic SCARB2 no eQTL no eQTL 
rs9268877 32431147 A 6 Intergenic HLA-DRA HLA-DPA1 Frontal cortex 3.1x10
-5
 
increased 
expression 
HLA-DRB1 
Cerebellum 5.2x10
-8
 
increased 
expression 
Anterior cingulate cortex 8.8x10
-8
 
Putamen 8.9x10
-7
 
HLA-DQA2 Cerebellum 1.3x10
-6
 
decreased 
expression 
rs676768 116030773 / 10 Intronic VWA2 no eQTL no eQTL 
rs10784359 40445750 / 12 Intronic SLC2A13 no eQTL no eQTL 
rs2893253 107067203 / 13 Intergenic EFNB2 no eQTL no eQTL 
rs199528 44843136 C 17 Intronic WNT3 LRRC37A2 Temporal cortex 3x10
-6
 
decreased 
expression 
RP11-
259G18.2 
Anterior cingulate cortex 
4x10
-14
 
decreased 
expression 
LRRC37A2 1.7x10
-12
 
KANSL1-
AS1 
4.5x10
-12
 
RP11-
259G18.3 
1.6x10
-11
 
LRRC37A2 
Caudate (basal ganglia) 
4.5x10
-20
 
KANSL1-
AS1 
6.6x10
-20
 
RP11-
259G18.2 
1.9x10
-19
 
RP11-
259G18.3 
3.5x10
-19
 
LRRC37A 5.4x10
-7
 
RP11-
259G18.3 
Cerebellar Hemisphere 
1.1x10
-18
 
LRRC37A2 5.7x10
-17
 
KANSL1-
AS1 
2.3x10
-16
 
RP11-
259G18.2 
2x10
-13
 
LRRC37A 2x10
-10
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs199528 44843136 C 17 Intronic WNT3 
LRRC37A2 Temporal cortex 3x10
-6
 
decreased 
expression 
RP11-
259G18.1 
Cerebellar Hemisphere 
4.6x10
-10
 
decreased 
expression 
MAPT-AS1 1.6x10
-8
 
MAPT 1.3x10
-7
 
increased 
expression 
RP11-
259G18.3 
Cerebellum 
2x10
-25
 
decreased 
expression 
KANSL1-
AS1 
3.9x10
-20
 
LRRC37A2 6.2x10
-19
 
RP11-
259G18.2 
1.6x10
-17
 
LRRC37A 4x10
-13
 
RP11-
259G18.1 
1.3x10
-12
 
MAPT 8.7x10
-12
 
increased 
expression 
MAPT-AS1 3.6x10
-8
 
decreased 
expression 
SPPL2C 1.3x10
-7
 
KANSL1 Hippocampus 1x10
-5
 
KANSL1-
AS1 
Cortex 
2.4x10
-18
 
RP11-
259G18.3 
5.1x10
-18
 
RP11-
259G18.2 
1.3x10
-17
 
LRRC37A2 2.5x10
-14
 
KANSL1-
AS1 
Frontal Cortex 
1.3x10
-20
 
RP11-
259G18.2 
1.5x10
-16
 
LRRC37A2 2.3x10
-16
 
RP11-
259G18.3 
8.4x10
-16
 
MAPT 1.3x10
-7
 
increased 
expression 
KANSL1-
AS1 
Hippocampus 
2.4x10
-16
 
decreased 
expression 
RP11-
259G18.3 
3.1x10
-13
 
RP11-
259G18.2 
7x10
-13
 
LRRC37A2 3.7x10
-12
 
KANSL1-
AS1 
Hypothalamus 1.3x10
-15
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs199528 44843136 C 17 Intronic WNT3 KANSL1 Hippocampus 1x10
-5
 
decreased 
expression 
LRRC37A2 
Hypothalamus 
7.6x10
-15
 
decreased 
expression 
RP11-
259G18.3 
1.6x10
-13
 
RP11-
259G18.2 
5.8x10
-13
 
LRRC37A 5.6x10
-8
 
KANSL1-
AS1 
Nucleus accumbens (basal 
ganglia) 
1.8x10
-20
 
RP11-
259G18.3 
1.4x10
-18
 
LRRC37A2 4.9x10
-17
 
RP11-
259G18.2 
3.4x10
-16
 
RP11-
259G18.1 
7.3x10
-7
 
KANSL1-
AS1 
Putamen (basal ganglia) 
2.5x10
-19
 
RP11-
259G18.3 
6.9x10
-15
 
LRRC37A2 3.1x10
-14
 
RP11-
259G18.2 
9.6x10
-11
 
LRRC37A 1x10
-6
 
RP11-
259G18.1 
1.6x10
-6
 
rs1358071 43803189 A 17 Intronic CRHR1 LRRC37A4 
Cerebellum 
7.4x10
-22
 
increased 
expression 
LRRC37A4P 
Anterior cingulate cortex 
1.9x10
-11
 
increased 
expression 
1.8x10
-16
 
RP11-
259G18.2 
1.6x10
-9
 
decreased 
expression 
Frontal cortex 3.6x10
-10
 
RP11-
707O23.5 
4.3x10
-9
 
Hippocampus 
4.7x10
-10
 LRRC37A2 5.3x10
-8
 
5.3x10
-7
 
RP11-
259G18.3 
7.5x10
-7
 
Medulla 2.7x10
-8
 
KANSL1-
AS1 
9.7x10
-7
 
Occipital cortex 
1.9x10
-11
 LRRC37A4P 
Caudate (basal ganglia) 
7.3x10
-15
 
increased 
expression 
5.5x10
-11
 LRRC37A2 1.7x10
-14
 
decreased 
expression 
Putamen 2.2x10
-6
 
RP11-
707O23.5 
4.5x10
-13
 
Substantia nigra 
7.3x10
-11
 
RP11-
259G18.2 
3.1x10
-12
 
2.4x10
-7
 
KANSL1-
AS1 
2.8x10
-11
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs1358071 43803189 A 17 Intronic CRHR1 
LRRC37A4 
Temporal cortex 
3.1x10
-12
 
increased 
expression 
RP11-
259G18.3 
Caudate (basal ganglia) 
1.1x10
-10
 
decreased 
expression 
1.1x10
-7
 LRRC37A 6.3x10
-6
 
Thalamus 
5.7x10
-12
 LRRC37A4P 
Cerebellar Hemisphere 
1.3x10
-15
 
increased 
expression 
5.2x10
-10
 PLEKHM1 4.0x10
-13
 
White matter 7.7x10
-6
 LRRC37A2 2.6x10
-12
 
decreased 
expression 
KANSL1 Hippocampus 6.1x10
-7
 
decreased 
expression 
RP11-
259G18.2 
1.5x10
-9
 
RP11-
259G18.3 
1.9x10
-9
 
RP11-
259G18.1 
2.6x10
-9
 
KANSL1-
AS1 
6.1x10
-9
 
LRRC37A 2.5x10
-8
 
RP11-
798G7.5 
5.9x10
-8
 
increased 
expression 
RP11-
707O23.5 
2.8x10
-7
 
decreased 
expression 
FMNL1 4.2x10
-7
 
increased 
expression 
CTD-
2020K17.1 
5.2x10
-6
 
MAPT 6.6x10
-6
 
LRRC37A4P 
Cerebellum 
5.3x10
-18
 
PLEKHM1 4.2x10
-17
 
RP11-
259G18.3 
5.6x10
-16
 
decreased 
expression 
LRRC37A2 3.3x10
-15
 
RP11-
259G18.2 
6.6x10
-15
 
RP11-
707O23.5 
2.6x10
-13
 
RP11-
259G18.1 
1.5x10
-10
 
LRRC37A 1.7x10
-10
 
KANSL1-
AS1 
7.1x10
-10
 
RP11-
798G7.5 
1.4x10
-9
 
increased 
expression 
MAPT 5.4x10
-9
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs1358071 43803189 A 17 Intronic CRHR1 
KANSL1 Hippocampus 6.1x10
-7
 
decreased 
expression 
MAPT-AS1 
Cerebellum 
6.2x10
-8
 
decreased 
expression 
FMNL1 2.7x10
-6
 
increased 
expression 
KANSL1-
AS1 
Cortex 
1.5x10
-14
 
decreased 
expression 
LRRC37A2 1.6x10
-11
 
RP11-
707O23.5 
2.7x10
-11
 
LRRC37A4P 3.2x10
-11
 
increased 
expression 
RP11-
259G18.3 
5.7x10
-11
 
decreased 
expression 
RP11-
259G18.2 
1.3x10
-10
 
CRHR1-IT1 1.3x10
-8
 
PLEKHM1 9.4x10
-7
 
RP11-
259G18.1 
7.8x10
-6
 
CRHR1 Medulla 2.9x10
-6
 
LRRC37A2 
Frontal Cortex 
2.5x10
-11
 
LRRC37A4P 9.3x10
-11
 
increased 
expression 
RP11-
259G18.2 
2.2x10
-10
 
decreased 
expression 
KANSL1-
AS1 
8.2x10
-10
 
RP11-
707O23.5 
9.8x10
-10
 
RP11-
259G18.3 
1.7x10
-9
 
DND1P1 1.6x10
-6
 
CRHR1-IT1 2.7x10
-6
 
MAPT 4.1x10
-6
 
increased 
expression 
LRRC37A4P 
Hippocampus 
2.0x10
-12
 
LRRC37A2 1.6x10
-11
 
decreased 
expression 
RP11-
259G18.2 
2.7x10
-11
 
KANSL1-
AS1 
4.1x10
-11
 
RP11-
707O23.5 
5.8x10
-11
 
RP11-
259G18.3 
2.5x10
-8
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs1358071 43803189 A 17 Intronic CRHR1 CRHR1 Medulla 2.9x10
-6
 
decreased 
expression 
CRHR1-IT1 
Hippocampus 
4.8x10
-8
 
decreased 
expression 
DND1P1 2.4x10
-6
 
LRRC37A2 
Hypothalamus 
1.1x10
-12
 
RP11-
707O23.5 
3.2x10
-11
 
KANSL1-
AS1 
8.7x10
-10
 
LRRC37A4P 1.8x10
-9
 
increased 
expression 
RP11-
259G18.2 
2.1x10
-8
 
decreased 
expression RP11-
259G18.3 
2.3x10
-8
 
LRRC37A4P 
Nucleus accumbens (basal 
ganglia) 
2.2x10
-16
 
increased 
expression 
KANSL1-
AS1 
2.3x10
-13
 
decreased 
expression 
RP11-
707O23.5 
1.2x10
-11
 
RP11-
259G18.3 
4.2x10
-11
 
LRRC37A2 5.8x10
-11
 
RP11-
259G18.2 
8.6x10
-9
 
CRHR1-IT1 1.0x10
-7
 
LRRC37A4P 
Putamen (basal ganglia) 
2.9x10
-12
 
increased 
expression 
LRRC37A2 1.5x10
-10
 
decreased 
expression 
KANSL1-
AS1 
2.9x10
-10
 
RP11-
707O23.5 
1.6x10
-9
 
RP11-
259G18.3 
4.1x10
-9
 
RP11-
259G18.2 
1.7x10
-8
 
CRHR1-IT1 5.8x10
-7
 
rs12964543 56543095 / 18 Intronic ZNF532 no eQTL no eQTL 
rs405509 45408836 / 19 Intergenic APOE no eQTL no eQTL 
rs4417745 241225364 / 2 Intergenic OTOS no eQTL no eQTL 
rs1328032 71420424 / 13 Intergenic DACH1 no eQTL no eQTL 
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Table 3. Summary of eQTL in brain from Braineac and GTEx (continued) 
rs2446406 51679783 / 15 Intronic GLDN no eQTL no eQTL 
rs7184882 73737373 C 16 In orf LOC101927998 no eQTL no eQTL 
rs6857 45392254 T 19 3’-UTR PVRL2 no eQTL no eQTL 
rs302665 87879627 / 11 Intronic RAB38 no eQTL no eQTL 
rs10507789 71409940  / 13 Intergenic DACH1 no eQTL no eQTL 
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DISCUSSION 
The current work shows that several genetic markers are jointly associated with increased risk for FTD, 
AD and PD. By leveraging recently developed and validated genetic methods, our findings indicate 
potential shared genetic architecture among these neurodegenerative diseases and suggest the 
polygenic nature of sporadic FTD where multiple pleiotropic loci with small effect size contribute to 
increased disease risk. To the best of our knowledge this is the first large-scale study assessing genetic 
overlap between sporadic FTD and AD, and sporadic FTD and PD. 
Using the conjunction FDR (which identifies loci jointly associated with two traits) we found 8 
polymorphisms specific to FTD-PD and 1 to FTD-AD; through the conditional FDR (which leverages 
secondary phenotypes, e.g. AD and PD, to improve statistical power for gene discovery) we identified 13 
novel FTD associated loci. Of note, all 9 conjunction FDR loci were also detected in the conditional FDR 
analyses supporting the notion that the shared polymorphisms increase risk for developing sporadic FTD. 
Across all analyses, we found notable relevance for the HLA, MAPT and APOE regions. 
Building on prior work implicating the involvement of the immune system in PD[26] and AD,[17] we found 
that rs9268877, on chromosome 6, intergenic between HLA-DRA and HLA-DRB5, is a shared marker 
between FTD and PD. The risk allele of this SNP was robustly associated with changes in expression of 
HLA-DPA1 (increased expression), HLA-DRB1 (increased expression) and HLA-DQA2 (decreased 
expression) in brain tissues. HLA-DPA1 is an HLA class II alpha chain paralogue presenting peptides 
derived from extracellular proteins;[27] this is of particular relevance as impairment of clearance of 
extracellular debris might increase risk of developing a neurodegenerative condition,[28] including FTD 
and PD. While HLA-DRB1 has functions similar to HLA-DPA1, HLA-DQA2 belongs to the HLA class II 
alpha chain family located in intracellular vesicles: it plays a central role in the peptide loading of MHC 
class II molecules and releasing the class II-associated invariant chain peptide (CLIP) molecule from the 
peptide binding site. This prevents the binding of self-peptide fragments prior to MHC II localization within 
the endolysosome.[29] Taken together, this data supports and further elucidates details about the role of 
immune system and endolysosomal processes in both FTD and PD. 
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Our results also point to the MAPT region as jointly involved in PD and FTD through two SNPs on 
chromosome 17 mapping to WNT3 (wingless-type MMTV integration site family member 3; rs199528) 
and CRHR1 (corticotropin releasing hormone receptor 1; rs1358071). The risk alleles of both markers, 
which tag the H1 MAPT-haplotype (Figure 4a), are associated with robust expression changes of 
LRRC37A2 (decreased expression), KANSL1 (decreased expression), LRRC37A4 (increased 
expression) and CRHR1 (decreased expression). The LRRC37A (leucine-rich repeat containing 37 
member) genes encode plasma membrane proteins that pass from the Golgi to the endoplasmic 
reticulum (ER) and extracellular areas through vesicle transport[30] reiterating that intracellular vesicle 
trafficking is a sensitive and potentially vulnerable process in the brain. The KANSL1 (KAT8 regulatory 
NSL complex subunit 1) gene encodes a nuclear protein targeting the DNA and involved in histone 
acetylation with the MLL1 and NSL1 complexes: disruption, mutations or haploinsufficiency of this gene 
have been associated with the 17q21.31 microdeletion syndrome.[31] CRHR1 encodes a G-protein 
coupled receptor for neuropeptides involved in diverse physiological processes including stress and 
immune responses.[32] Overall, this data strongly suggests that the H1 MAPT-haplotype contributes to 
increased risk for both FTD and PD and its effect is likely mediated by modulating changes in the 
expression profiles of functionally important cis-genes. 
We found evidence for involvement of the APOE region in FTD. We detected a genome-wide significant 
association signal in sporadic FTD for rs6857 (3’UTR in PVRL2; p-value = 2.21 x 10
-12
) and identified 
rs405509, intergenic between TOMM40 (translocase of outer mitochondrial membrane 40) and APOE 
(apolipoprotein E), as jointly associated with both FTD and AD. Rs6857 and rs405509 are in linkage 
equilibrium (LE; r
2
=0.1) and are part of two separate haplotypes (Figure 4b): (i) one spanning 12 Kbp 
(including 13 SNPs [rs142042446, rs12972156, rs12972970, rs34342646, rs283811, rs283815, 
rs71352238, rs184017, rs2075650, rs34404554, rs11556505, rs778934950 and rs59007384] with r
2
 ~0.8) 
and encompassing PVRL2 and TOMM40 for rs6857 (haplotype a), and; (ii) one spanning 14 Kbp 
(including 10 SNPs [rs157584, rs71337246, rs7157588, rs7157590, rs1160985, rs760136, rs741780, 
rs1038025, rs34215622 and rs7259620] with r
2
 ~0.8) and encompassing TOMM40 and APOE for 
rs405509 (haplotype b). Our data indicate that rs6857 increases risk of FTD, whilst this was not the case 
for rs405509. No SNP within either haplotype (a or b) was functionally associated with cis-regulatory 
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effects. A large body of evidence implicates APOE as a strong genetic risk factor for AD. Whether it is a 
genetic modifier of disease risk with non-AD neurodegenerative diseases is still unclear. In this respect, 
several studies in the literature have highlighted this locus as a potential risk factor, with variable effect 
size, for a variety of conditions including vascular dementia (VD), amyotrophic lateral sclerosis (ALS), PD 
and dementia with Lewy bodies (DLB).[33] Although early work did not find a clear association between 
the APOE locus and FTD,[34] more recent studies suggest that it might associate with FTD risk[35-37] 
and accelerate frontotemporal brain atrophy.[38] Given potential overlap between patients diagnosed with 
clinical FTD and AD,[39] it is unclear whether the current findings reflect a genuine association with FTD 
or might be inflated by subtle presence of AD or FTD cases in either original study cohort. Nonetheless, 
this data raises the question whether the detected PVRL2 SNP tags an FTD-specific risk disease 
haplotype: future work will be required to further characterize the potential role of this locus – in particular, 
haplotype a – in FTD. 
We also detected several pleiotropic loci between FTD and PD, in addition to HLA, MAPT and APOE. 
The marker on chr 4, rs7664889, is intronic to the SCARB2 (scavenger receptor class B member 2) gene 
that encodes a glycoprotein locating to the membrane of lysosomes and endosomes further supporting 
the notion of impacted endolysosomal tracts in both FTD and PD. The marker on chromosome 12, 
rs10784359 maps to the intronic region of SLC2A13 (solute carrier family 2 member 13) a gene, which is 
part of the extended locus that includes LRRK2 indicating that this region may also mediate FTD risk.[40] 
Some limitations might apply to studies of this kind. Particularly, in the original works, the diagnoses of 
FTD, AD and PD were established clinically. This has the potential to introduce subtle clinical overlap 
across cohorts, thus assessments in large pathology confirmed cohorts is the next valuable and 
warranted step to take. However, it must be acknowledged that such ad hoc cohorts are currently not yet 
available.  
Considered together with prior work, our results overall are a first step in the process of decrypting 
common underpinnings of FTD, AD and PD: they suggest that a subset of genetic markers in the HLA 
and MAPT-H1 regions (and potentially the APOE cluster) might be jointly involved in these 
neurodegenerative disorders. In the case of the HLA and MAPT loci, differentially expressed genes in 
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distinct brain regions might account for the clinical and phenotypic differences observed across these 
disorders.[41] Of note, the relevant pleiotropic SNPs that we found in the HLA and MAPT regions do 
appear to exert their effect by influencing expression changes in cis-genes involved in immune response, 
endolysosomal processes, intracellular vesicular trafficking and DNA/chromatin-associated metabolism, 
further supporting the notion of involvement of these processes in neurodegenerative disease, including 
FTD.[42] More work will be needed to further characterize our pleiotropic signals, which might hold 
promise in the future for developing global preventive and therapeutic strategies for FTD, AD and PD. 
In summary, we here identified (i) genetic overlap between FTD and AD and FTD and PD, and (ii) novel 
loci influencing FTD pathobiology with small effect size illustrating that a substantial polygenic component 
contributes to FTD risk. 
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FIGURE LEGENDS 
 
Figure 1.  Fold enrichment plots of enrichment versus nominal -log10 p-values (corrected for inflation) in 
frontotemporal dementia (FTD) below the standard GWAS threshold of p < 5x10
-8
 as a function of 
significance of association with Alzheimer’s disease (AD, panel A) and Parkinson’s disease (PD, panel B) 
and at the level of -log10(p) ≥ 0, -log10(p) ≥ 1, -log10(p)  ≥ 2 corresponding to p ≤ 1, p ≤ 0.1, p ≤ 0.01, 
respectively. Blue line indicates all SNPs.  
 
Figure 2. ‘Conjunction’ (a) and ‘conditional’ (b) Manhattan plots of conjunction and conditional –log10 
(FDR) values for frontotemporal dementia (FTD) (black) and FTD given Alzheimer’s disease (AD; 
FTD|AD, red) and Parkinson’s disease (PD; FTD|PD, green). SNPs with conditional and conjunction –
log10 FDR > 1.3 (i.e. FDR < 0.05) are shown with large points. A black line around the large points 
indicates the most significant SNP in each LD block and this SNP was annotated with the closest gene, 
which is listed above the symbols in each locus. For additional details, see Supplemental Information. 
 
Figure 3. Forest plots for (a) rs6857 on chromosome 19 and (b) rs1358071 on chromosome 17. 
 
Figure 4. (a) MAPT-locus on chromosome 17. The two SNPs, rs1358071 and rs199528 are shared 
between FTD and PD. Either SNP is in LD with rs1052553 whose major allele (A) tags the H1 MAPT-
haplotype. The major alleles of rs1358071 and rs199528 are also the effect alleles and they are in LD 
with rs1052553 (r
2
=0.75 and 0.84, respectively). Thus the effect at this locus is H1 driven. (b) APOE-
locus. The two haplotypes a and b are depicted. Haplotype a is the one driven by rs6857 with 13 SNPs in 
LD (r
2
~0.8; font color: blue). Haplotype b is the one driven by rs405509 with 10 SNPs in LD (r
2
~0.8; font 
color: black). Rs6857 and rs405509, and the respective haploytpes a and b, are in LE (r
2
~0.1). 
 
 
